Skip to main content
. 2017 Apr 27;2017:1423683. doi: 10.1155/2017/1423683

Table 1.

HMGB1 and other biomarkers of patients with ovarian cancer treated with peptide vaccination.

Case Overall survival
(months)
IgG response CTL response Epitope spreading HMGB1
(ng/mL)
MDSC (%) SAA (mg/dL) CRP (mg/dL) IL-6 (pg/mL)
Pre Post Pre Post Pre Post Pre Post Pre Post
F-018 19.1 No No No <2.5 2.7 NC 0.3 0.6 I 10.5 5.2 D 0.3 0.4 NC 2 11 I
FOV-003 20.0 Yes Yes Yes 5.9 <2.5 D 0.2 0.3 NC 1.5 19.5 I 0.0 0.9 I 0 0 NC
FOV-004 5.3 Yes Yes Yes 10.6 <2.5 D 0.6 0.5 NC 3.2 11.6 I 0.1 0.3 I 2 3 NC
FOV-005 11.4 Yes Yes Yes 5.7 <2.5 D 0.6 0.5 NC 0.4 12.7 I 0.2 0.8 I 0 2 I
FOV-006 34.7 Yes Yes Yes <2.5 2.9 NC 0.5 0.5 NC 0.7 1.1 NC 0.1 0.2 I 0 0 NC
FOV-008 14.1 Yes Yes No 4.3 2.8 NC 0.1 0.1 NC 2.4 18.8 I 0.1 0.9 I 0 0 NC
FOV-009 8.1 Yes Yes Yes 4.5 3.9 NC 0.5 0.4 NC 20.4 20.8 NC 0.7 1.0 NC 0 0 NC
FOV-010 >69.7 Yes Yes Yes <2.5 <2.5 NC 0.1 0.3 I 0.3 7.9 I 0.0 0.5 I 0 0 NC
FOV-012 16.1 Yes Yes No <2.5 <2.5 NC 1.1 1.6 NC 6.3 1.7 D 0.1 0.5 I 0 0 NC
FOV-013 4.0 No Yes No <2.5 3.7 NC 0.1 0.1 NC 11.8 11.8 NC 0.9 0.9 NC 10 23 I
FOV-014 32.2 Yes Yes Yes 5.0 3.5 NC 0.3 0.3 NC 12.8 14.8 NC 0.1 0.3 I 0 0 NC
FOV-015 10.7 Yes No No 4.0 10.4 I 1 1.2 NC 2.9 14.9 I 0.6 0.9 NC 0 0 NC
FOV-016 29.5 Yes Yes No 3.8 9.2 I 0.6 0.4 NC 12.1 13.8 NC 1.0 0.9 NC 6 12 I
FOV-019 >61.3 Yes No Yes 2.7 4.9 NC 0.6 0.4 NC 1.4 5.6 I 0.1 0.6 I 0 0 NC
FOV-022 22.0 Yes Yes No 4.6 3.2 NC 0.5 § 1.8 3.6 I 0.4 0.1 D 0 0 NC
FOV-023 16.8 Yes Yes Yes 6.5 3.5 NC 0.1 0.2 I 13.8 11.9 NC 1.5 2.3 NC 2 15 I
FOV-024 8.7 No No No <2.5 6.1 I 0.2 0.1 D 8.9 11.8 NC 0.8 2.3 I 0 17 I
FOV-026 >45.7 Yes Yes Yes 3.1 5.2 NC NC 4.2 5.5 NC 0.1 0.1 NC 0 0 NC
FOV-027 36.9 Yes Yes Yes 12.8 7.8 NC 0.2 0.6 I 2.6 4.8 NC 0.0 0.6 I 0 0.5 I
FOV-028 >42.7 Yes Yes No 17.4 <2.5 D 0.2 0.7 I 0.3 0.4 NC 0.3 0.0 D 1.2 1.1 NC
FOV-030 22.0 Yes Yes Yes 8.5 12.5 NC 0.4 0.5 NC 6.1 22.5 I 0.4 4.1 I 0 8 I
FOV-031 19.6 Yes No Yes 4.2 4.7 NC 0.3 0.3 NC 8.2 9.5 NC 0.1 0.2 I 0 0 NC
FOV-032 12.6 Yes Yes Yes 4.2 3.8 NC 0.6 0.3 D 0.3 5.2 I 0.2 2.2 I 0 7.2 I
FOV-033 26.9 Yes Yes Yes <2.5 3.5 NC 0.4 0.5 NC 1.6 12.9 I 0.1 1.8 I 0 2.7 I
FOV-034 26.8 Yes No Yes 12.2 6.7 NC 0.7 0.6 NC 0.6 0.7 NC 0.1 0.3 I 0 0 NC
FOV-036 24.0 Yes Yes Yes 5.4 4.2 NC 0.2 0.2 NC 1.8 19.3 I 1.9 4.4 I 0.9 26.2 I
FOV-037 4.6 No No No 7.3 2.6 D 0.7 0.4 NC 0.7 15.8 I 1.4 4.4 I 4.6 19.8 I
FOV-038 7.9 No No No 15.1 18.6 NC 1.4 1.1 NC 11.6 20.9 NC 1.7 3.6 I 4.5 14.9 I
FOV-039 >10.3 Yes No No 3.0 <2.5 NC § 0.9 1.3 NC 0.4 0.7 NC 0 1.6 I
FOV-040 2.2 No No No 6.1 <2.5 D 0.8 0.6 NC 14.1 15.5 NC 1.0 1.8 NC 3.9 7.2 NC
FOV-041 18.3 Yes No Yes 8.6 3.6 D 0.8 0.5 NC 2.1 2.3 NC 0.1 0.1 NC 0 0 NC
FOV-042 >37 Yes No No 4.0 4.0 NC 0.3 0.1 D 0.3 0.4 NC 0.1 0.1 NC 0 0 NC
FOV-043 29.2 Yes Yes Yes 2.9 4.6 NC 0.2 0.3 NC 13.4 1.3 D 2.0 0.3 D 12.5 0 D
FOV-044 19.6 Yes Yes Yes 10.4 2.9 D 0.1 0.2 I 1.0 10.1 I 0.0 1.3 I 0 0 NC
FOV-045 8.3 Yes Yes Yes 6.3 5.5 NC 0.2 0.3 NC 1.6 18.8 I 0.7 3.6 I 1.8 10.7 I
FOV-046 6.6 Yes Yes No 3.7 <2.5 NC 0.3 0.1 D 21.0 16.0 NC 3.8 4.1 NC 11.4 17.1 NC
FOV-047 >35.5 Yes Yes Yes 8.7 3.8 D 0.5 0.8 NC 6.3 1.6 D 0.4 0.2 D 16.3 1.4 D
FOV-048 4.7 Yes No No 7.0 <2.5 D 0.5 0.3 NC 21.9 18.3 NC 3.9 4.9 NC 2.1 17.6 I
FOV-049 22.0 Yes No Yes 6.6 4.8 NC 1 0.7 NC 4.2 2.6 NC 0.2 0.4 I 0 0 NC

§Blood samples of patients were collected before (pre) and after (post) the 1st cycle of vaccination, and HMGB1 and other biomarkers were measured. Response criteria of IgG, CTL, and epitope spreading were previously reported; post values were compared with prevalues, and if the postvalue was ≥150% or ≤50% of prevalue, it was considered increased or decreased, respectively. I: increased; D: decreased; NC: no change; samples were not available.